Full Data For Intercept's Liver Disease Drug Show Rivals Where To Differentiate

Full Phase III data for Intercept Pharmaceuticals Inc.'s recently approved rare liver disease drug, Ocaliva, have highlighted potential treatment gaps for upcoming pipeline drugs, including candidates from Gilead Sciences Inc., Novartis AG, Shire Pharmaceuticals plc and GlaxoSmithKline plc.

Despite Intercept Pharmaceuticals Inc. winning US FDA approval in May for its chronic liver disease therapy Ocaliva (obeticholic acid) – which became the first new drug for the treatment of rare liver disease primary biliary cholangitis (PBC) to reach the market in more than 20 years – full Phase III data published in the New England Journal of Medicine have highlighted some flaws in the study exposing potential gaps that could be filled by upcoming pipeline drugs.

On May 27, 2016 the FDA granted accelerated conditional approval for Intercept's Ocaliva for the treatment of PBC, a chronic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Pipeline Watch: Ten Approvals And Seventeen Phase III Readouts

23 Jun 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Defying Gravity: Five Drugs That Surpassed Their Sales Forecasts

20 Jun 2025

• By Edwin Elmhirst

Many assets outperform their pre-launch sales predictions despite the frequent overestimation of forecasts within the industry. In this article, Scrip highlights several such assets and the factors that influenced their predictions.

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

19 Jun 2025

• By Alexandra Shimmings

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.